Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesBioMark Diagnostics Inc

BioMark Diagnostics Inc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
0.42 CAD -0.03 ( 6.67%)
Last update at 2026-11-11T14:30:00Z
VOLUME
2000
Market Cap
60.95M

Momentum Score

…

Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.42
Low
0.42
High
52 Week Price Range
0.24
Low
0.64
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

BioMark Diagnostics Inc is a Canada-listed firm that, based on limited public disclosures, operates in the medical diagnostics sector offering diagnostic tests and related services. Long-term growth drivers may include increasing demand for diagnostic testing from aging populations and broader adoption of new diagnostic platforms, which could support market expansion. Investors may find exposure to the healthcare diagnostics field attractive if the company achieves commercial traction and regulatory milestones.

Material risks include limited public information and likely thin trading, execution and regulatory approval challenges for diagnostic products, and reliance on external financing to fund development and commercialization.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.45
Dividend Yield
-
Revenue TTM
0.09M
Revenue Per Share
0.00
Gross Profit TTM
0.09M
Debt / Equity
-1.39
ROE
-504.79%
Net Debt
0.25M
ROCE
-112.40%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax -1.93M -1.43M -1.84M -1.45M -1.09M
Net income -1.93M -1.43M -1.84M -1.45M -1.09M
Selling general administrative 1.19M 0.93M 1.15M 0.86M 0.96M
Reconciled depreciation 0.40M 0.39M 0.39M 0.18M 0.01M
Ebit - - - -1.28M -1.03M
Ebitda - - -1.35M -1.22M -1.08M
Operating income -2.14M -1.61M -1.93M -1.40M -1.08M
Interest expense 0.06M 0.12M 0.11M 0.05M 0.00M
Interest income 0.06M 0.11M 0.11M 0.05M 0.00M
Net interest income -0.06M -0.11M -0.11M -0.05M -0.00M
Total revenue 0.15M 0.16M 0.15M 0.04M 0.00M
Total operating expenses 2.06M 1.48M 1.89M 1.45M 1.08M
Total other income expense net 0.04M 0.00M - -0.00M -0.01M
Net income from continuing ops -1.93M -1.43M -1.84M -1.45M -1.09M
Net income applicable to common shares -1.93M -1.43M -1.84M -1.45M -1.09M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 3.13M 1.09M 0.73M 1.47M 0.95M
Total liab 1.39M 1.70M 1.88M 2.11M 1.03M
Total stockholder equity 1.74M -0.61M -1.15M -0.64M -0.08M
Other current liab - - - 0.01M 0.11M
Common stock 13.78M 10.14M 8.24M 7.12M 6.88M
Capital stock 13.78M 10.14M 8.24M 7.12M 6.88M
Retained earnings -15.77M -13.45M -11.62M -10.12M -8.59M
Other assets 0.03M 0.03M 0.01M - -
Cash 2.48M 0.16M 0.07M 0.38M 0.88M
Cash and equivalents 2.48M 0.16M 0.07M 0.38M 0.88M
Total current liabilities 1.23M 1.24M 1.66M 1.50M 0.92M
Net debt - - 0.25M - -
Short term debt 0.00M 0.00M 0.23M 0.14M 0.00M
Short long term debt - - 0.33M 0.14M -
Short long term debt total - - - - 0.11M
Other stockholder equity - - - 0.66M 0.00M
Property plant equipment 0.45M 0.85M 0.59M 0.97M 0.03M
Total current assets 2.64M 0.20M 0.13M 0.50M 0.92M
Long term investments 0.00M 0.00M 0.00M 0.00M 0.00M
Net tangible assets - - - -0.64M -0.08M
Net receivables 0.16M 0.04M 0.03M 0.08M 0.03M
Long term debt - - 0.00M 0.10M 0.09M
Accounts payable 0.27M 0.14M 0.22M 0.13M 0.03M
Non current assets total 0.49M 0.89M 0.61M 0.97M 0.03M
Capital lease obligations 0.45M 0.81M 0.50M 0.81M 0.03M
Long term debt total 0.16M 0.45M 0.22M 0.61M 0.11M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments -0.00M -0.00M -0.01M -0.06M -0.00M
Change to liabilities - - - 0.11M -0.08M
Total cashflows from investing activities -0.00M -0.00M -0.01M -0.06M -0.00M
Net borrowings -0.41M -0.73M -0.30M -0.13M 0.02M
Total cash from financing activities 3.42M 1.07M 0.61M 0.77M 1.08M
Change to operating activities - - - -0.02M -0.02M
Net income -1.93M -1.43M -1.84M -1.45M -1.09M
Change in cash 2.33M 0.08M -0.31M -0.49M 0.27M
Begin period cash flow 0.16M 0.07M 0.38M 0.88M 0.61M
End period cash flow 2.48M 0.16M 0.07M 0.38M 0.88M
Total cash from operating activities -1.09M -0.98M -0.91M -1.20M -0.81M
Issuance of capital stock 3.61M 1.54M 0.96M 0.66M 0.08M
Depreciation 0.40M 0.39M 0.39M 0.18M 0.01M
Other cashflows from investing activities - - - 0.00M -0.00M
Change to account receivables - - - -0.05M -0.01M
Sale purchase of stock 3.61M 1.54M 0.64M 0.23M 0.91M
Other cashflows from financing activities 0.22M 0.26M 0.27M 0.69M -0.27M
Change to netincome - - - 0.03M 0.38M
Capital expenditures 0.00M 0.00M 0.01M 0.06M 0.06M
Change in working capital 0.00M -0.09M 0.14M 0.04M 0.24M
Stock based compensation 0.37M 0.08M 0.33M 0.20M 0.40M
Other non cash items 0.06M 0.06M 0.07M 0.03M 0.00M
Free cash flow -1.10M -0.99M -0.92M -1.26M -0.46M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BUX
BioMark Diagnostics Inc		 -0.03
6.67%		 0.42 - - 664.18 119.98 657.92 -27.36
SONA
Sona Nanotech Inc		 -
-%		 0.28 - - 495.02 110.83 434.31 54.97
IZO
Izotropic Corporation		 -
-%		 0.12 - 2.27 - 114.27 - -5.29

Profile*

BioMark Diagnostics Inc

Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.

3851 Shell Road, Richmond, BC, Canada, V6X 2W2

604 370 0779

https://www.biomarkdiagnostics.com

Name Title Year Born
Mr. Rashid Ahmed Maula Bux B.Sc., MBA Founder, CEO, President & Director NA
Ms. Guoyu Huang MBA Chief Financial Officer NA
Mr. Brian Kai-Ming Cheng B.Sc., M.Sc. Chief Technical Officer & Independent Director NA
Dr. Jeff Haince Ph.D. GM & Chief Scientific Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…